Wednesday, April 20
6:30 a.m.–8:30 a.m. S36: Update in Muscle Disorders
6:30 a.m. S36.001 Anti-cN1A Autoantibody Seropositivity Is Associated with Increased Mortality Risk in Inclusion Body Myositis —James Lilleker, Anke Rietveld (joint first author), Umesh Badrising, Olivier Benveniste, Karina Gheorghe, Michael Hanna, Megan Herbert, David Hilton-Jones, Janine Lamb, Bryan Lecky, Ingrid Lundberg, Pedro Machado, Kubéraka Mariampillai, James Miller, Matt Parton, Maikel Peeters, Stephen Pye, Mark Roberts, Sabrina Sacconi, Christiaan Saris, Robert Cooper, Ger Pruijn, Hector Chinoy, Baziel van Engelen
6:45 a.m. S36.002 Limb Girdle Muscular Dystrophy Due to Calpainopathy Also Exists in a Dominantly Inherited Form —John
Vissing, Rita Barresi, Nanna Witting, Marijke van Ghelue, Laurence Bindoff, Straub Volker, Hanns Lochmuller, Christoph Wahl, Christoffer Jonsrud, Morten Duno
7:00 a.m. S36.003 Disease-Specific Splicing Changes Are Seen in Children with Congenital Myotonic Dystrophy —Donald
McCorquodale, Katie Mayne, Diane Dunn, Brith Otterud, Nicholas Johnson, Robert Weiss
7:15 a.m. S36.004 A Novel Glycogenin-1 Gene Mutation in a Family with Late-onset Proximal Myopathy —Corrado Angelini, Marina
Fanin, Vincenzo Nigro, Annalaura Torella, Marco Savarese
Scientific Platform Sessions Due to Heteroplasmic Mitochondrial DNA (mtDNA) Mutations —Ronald
Haller
8:15 a.m. S36.008 Revisiting the Clinical, Histochemical and Molecular Spectrum of AdultOnset AdPEO Associated with the C10Orf2 (PEO1) Mutation —Grainne Gorman, Kate Craig, Carl Fratter, Yi Shiau Ng, Andrew Purvis, Robert Field, Emma Blakely, Joanna Poulton, Robert McFarland, Doug Turnbull, Robert Taylor
S37: Risk Factors for Multiple Sclerosis
6:30 a.m. S37.001 Dietary Intake of Sodium and Other Minerals and the Risk of Multiple Sclerosis —Marianna Cortese, Tanuja Chitnis, Alberto Ascherio, Kassandra Munger
6:45 a.m. S37.002 Increased Sodium Intake Is Not Associated with MS Activity or Progression in BENEFIT —Kathryn
Fitzgerald, Kassandra Munger, Mark Freedman, Hans Hartung, Xavier Montalban, Gilles Edan, Frederik Barkhof, Ernst-Wilhelm Radue, Ludwig Kappos, Gustavo Suarez, Alberto Ascherio
7:00 a.m. S37.003 Smoking Cessation Decelerates Brain Volume Loss in Patients with Multiple Sclerosis —Navid Seraji-Bozorgzad, Fen Bao, Sara Razmjou, Christina Caon, Alexandros Tselis, Carla Santiago Martinez, Imad Zak, Evanthia Bernitsas, Omar Khan
7:30 a.m. S36.005 Silencing of Myotonic Dystrophy Protein Kinase (DMPK) Does Not Affect Cardiac or Muscle Function in Mice —Samuel Carrell, Ellie Carrell, David
7:15 a.m. S37.004 Physical Comorbidities Are Associated with an Increased Risk of Psychiatric Comorbidity in Multiple Sclerosis —
7:45 a.m. S36.006 Electrical Impedance Myography Is Reliable and Correlates to Measures of Facioscapulohumeral Muscular Dystrophy Disease Severity —Jeffrey
7:30 a.m. S37.005 Multiple Sclerosis Lesions Show Perturbations in Cerebral Microbiota —
Auerbach, Sanjay Pandey, Frank Bennett, Robert Dirksen, Charles Thornton
Statland, Chad Heatwole, Katy Eichinger, Nuran Dilek, William Martens, Alrabi Tawil
8:00 a.m. S36.007 Exercise Training Normalizes Mitochondrial Function in Myopathies
Scientific Platform Sessions
Ruth-Ann Marrie, Scott Patten, Jamie Greenfield, Helen Tremlett, Christina Wolfson, Sharon Warren, Larry Svenson, Nathalie Jette, John Fisk
William Branton, Jian Lu, Michael Surette, Robert Holt, John Lind, Jon Laman, Christopher Power
7:45 a.m. S37.006 Novel Multiple Sclerosis Genetic Risk Factors Are Involved in Epigenetic
Regulation —Dorothea Buck, Till
Andlauer, Antonios Bayas, Klaus Berger, Achim Berthele, Elisabeth Binder, Theresa Dankwoski, Andre Franke, Ralf Gold, Stefan Herms, Georg Homuth, Karl-Heinz Joeckel, Tim Kacprowski, Bernd Kieseier, Tania Kuempfel, Matthias Laudes, Wolfgang Lieb, Volker Limmroth, Ralf Linker, Susanne Moebus, Martina Mueller-Nurasyid, Antonella Mulas, Markus Noethen, Friedemann Paul, Martin Stangel, JanPatrick Stellmann, Konstantin Strauch, Bjorn Tackenberg, Florian Then Bergh, Hayrettin Tumani, Frank Weber, Peter Weber, Heinz Wiendl, Brigitte Wildemann, Uwe Zettl, Andreas Ziegler, Ulf Ziemann, Frauke Zipp, Francesco Cucca, Bertram Müller-Myhsok, Bernhard Hemmer
8:00 a.m. S37.007 Grey Matter Lesion Signature of Multiple Sclerosis —Jun-ichi Satoh, Yoshihiro Kino
8:15 a.m. S37.008 Multiple Sclerosis Clinical Characteristics in MolecularlyDefined Patient Populations —Ahmed
Enayetallah, Raghavendra Hosur, Richard Ransohoff, Jaya Goyal
S38: General Neurology: Therapeutics
6:30 a.m. S38.001 Edaravone, a Free Radical Scavenger, Delays Symptomatic and Pathological Progression of Wobbler Mouse Motor Neuron Disease —Ken Ikeda, Yasuo Iwasaki
6:45 a.m. S38.002 Hematopoietic Stem Cell Transplantation in Late-Onset Krabbe Disease Halts Demyelination and Axonal Loss: A 4-Year Longitudinal Case Study —Cornelia Laule, Elham Shahinfard, Burkhard Mӓdler, Irene Vavasour, Jing Zhang, Ritu Aul, David Li, Alex MacKay, Sandra Sirrs
7:00 a.m. S38.003 Phase 2 Open-Label Extension Study (OLE) of Patisiran, an Investigational RNAi Therapeutic for Familial Amyloid Polyneuropathy (FAP) —David Adams, Teresa Coelho, Isabel Conceicao, Marcia Waddington-Cruz, Hartmut Schmidt, Juan Buades, Josep Campistol, Jean Pouget, John Berk, Rick Falzone, Lindsey White,
$ A registration fee is required L The program is one of the AAN Leadership University sessions S The course is part of a Subspecialty in Focus track I The program is one of the I Talk sessions
110 2016 AAN Annual Meeting Abstract Listing
Brian Bettencourt, Jeff Cehelsky, Sara Nochur, Akshay Vaishnaw, Kirsten Gruis, Jared Gollob, Ole Suhr
7:15 a.m. S38.004 Functional and Imaging Studies of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-350 in a Clinically Relevant Murine Model of Closed Head Injury (CHI) —Claire Drolen, Haichen Wang, Talaignair Venkatraman, Chuan Fang, Yanli Tan, Sharon Tamir, Sharon Shacham, Christopher Lascola, Daniel Laskowitz
7:30 a.m. S38.005 Phase 1 Safety and Pharmacokinetics of the Novel Enzyme Replacement Therapy NeoGAA in Treatment-Naïve and Alglucosidase Alfa-Treated LateOnset Pompe Disease Patients —Jaya
Trivedi, Ans Van Der Ploeg, Richard Barohn, Barry Byrne, Claude Desnuelle, Ozlem Goker-Alpan, Shafeeq Ladha, Pascal Laforet, Eugen Mengel, Alan Pestronk, Jean Pouget, Benedikt Schoser, Volker Straub, Philip Van Damme, John Vissing, Peter Young, Raheel Shafi, Kerry CulmMerdek, Gerard Short, Loren Pena, and the NeoGAA Investigator Group
7:45 a.m. S38.006 Phase 1 Exploratory Efficacy of the Novel Enzyme Replacement Therapy NeoGAA in Treatment-Naïve and Alglucosidase Alfa-Treated Late-Onset Pompe Disease Patients —Loren Pena,
Richard Barohn, Barry Byrne, Claude Desnuelle, Ozlem Goker-Alpan, Shafeeq Ladha, Pascal Laforet, Eugen Mengel, Alan Pestronk, Jean Pouget, Benedikt Schoser, Volker Straub, Jaya Trivedi, Philip Van Damme, John Vissing, Peter Young, Beth Thurberg, Kerry Culm-Merdek, Gerard Short, Ans van der Ploeg, and the NeoGAA Investigator Group
8:00 a.m. S38.007 The Effect of Bolus Volume and Mechanical Forces on the Biodistribution of ASOs Following Lumbar Intrathecal Administration in Cynomolgus Monkeys —Daniel Wolf,
Jenna Sullivan, Curt Mazur, Eric Swayze, Berit Powers, Jack Hoppin, Ajay Verma
8:15 a.m. S38.008 Kinetics of ASO Distribution and Pharmacodynamics in the CNS After an Intrathecal Bolus Dose in Rat —Eric Swayze, Berit Powers, Fredrik Kamme, Curt Mazur, Daniel Wolf, Jenna Sullivan, Ajay Verma
Learning Lab Excitement of Discovery
Health & Wellness
Real World of Neurology
The program is part of the Experiential Learning Area sessions